Who is sponsoring NCT06813924?

NCT06813924 is sponsored by Novo Nordisk A/S.

What condition does NCT06813924 study?

NCT06813924 studies Healthy Volunteers Sickle Cell Disease, Thalassemia.

What drugs are being tested in NCT06813924?

Interventions: Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin.

What is the status of NCT06813924?

NCT06813924 is currently COMPLETED.

Last reviewed 2025-09-25 · How we verify

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

NCT06813924 PHASE1 COMPLETED

The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.

Details

Lead sponsor	Novo Nordisk A/S
Phase	PHASE1
Status	COMPLETED
Enrolment	37
Start date	Thu Feb 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Healthy Volunteers Sickle Cell Disease, Thalassemia

Interventions

Etavopivat
Digoxin
Pitavastatin
Metformin
Midazolam
Rosuvastatin

Countries

United States